Joint Formulary & PAD

Cinacalcet hydrochloride - Primary Hyperparathyroidism

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

See narrative
Formulations :
  • Tablets
Associated Icons :
SPC
Restrictions / Comments :

Documentation

  • No records returned.

PAD Profile

ChemicalSubstance :
Cinacalcet hydrochloride
Indication :
Primary Hyperparathyroidism
Group Name :
Keywords :
Brand Names Include :
Important Information :
Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Supporting Documents :
0

Other Indications

Below are listed other indications that Cinacalcet hydrochloride is used to treat.

Other Drugs

Below are listed other drugs that are used to treat Primary Hyperparathyroidism.

  • No records returned.

Committee Recommendations (1)

This drug/device has not yet been assessed for formulary status. but is on the APC work-plan. 

This drug/device has not yet been evaluated by the Surrey Heartlands ICS Area Prescribing Committee (APC).  As such, advice regarding safety, effectiveness (including cost-effectiveness) and its place in therapy is yet to be determined. It is recommended that clinicians contact their medicines management team for further information and advice before prescribing this drug / device.

This advice will be updated after consideration by the APC.